A new drug intended to treat low sexual desire in women has been approved by the US Food and Drug Administration. Addyi (flibanserin) is the first pharmaceutical for this condition, which is known as hypoactive sexual desire disorder (HSDD).
H. Lundbeck A/S produced some promising sales figures in its report for the first half year but this was overshadowed by another, more severe, cost cutting exercise by its newly appointed chief executive, Kåre Schultz.
Researchers at the University of Edinburgh’s Roslin Institute have discovered that aggregations of lymphoid tissue that are found in the small intestine have a role in prion-intermediated diseases.
A potential biomarker has been identified that could help physicians decide whether patients with HER2 + breast cancer will benefit from a combination therapy. According to a report in The Oncologist, patients with PIK3CA mutations are far less likely to respond to combination therapy than others.
Researchers at the University of Heidelberg have discovered that the Ebola virus needs cholesterol to create its cytotoxic effect. Using lipid-lowering agents, including a statin, the researchers were able to reduce the amount of cholesterol in cell cultures in an experiment and suppress the virus’ damage.
Merck & Co Inc has announced plans to collaborate with the MD Anderson Cancer Center in Texas to investigate combinations of its checkpoint antibody Keytruda (pembrolizumab) with other agents as possible treatments for three solid tumours.
A Phase 2 study of venetoclax, a new drug for chronic lymphocytic leukaemia (CLL), has shown a clinically meaningful reduction in cancer cells in patients with a specific genetic mutation known as the 17p deletion. The patients all had refractory CLL.
Researchers at the Max Planck Institute for Heart and Lung Research in Germany have identified a regulatory mechanism that could be a factor in the development of high blood pressure, a primary risk factor for many cardiovascular diseases.
Evotec AG increased its revenue by 37% to €55 million in the first half year, helped by favourable exchange rates, milestone payments and fees from pharmaceutical partners for whom it provides services. For the year as a whole, the company expects revenue to grow by 35%.
Merus BV of the Netherlands has secured another legal victory over Regeneron Pharmaceuticals Inc in a battle over intellectual property rights to transgenic mouse technology for the production of therapeutic antibodies.